JPH02503919A - 自己抗原の経口投与による自己免疫疾患の治療法 - Google Patents
自己抗原の経口投与による自己免疫疾患の治療法Info
- Publication number
- JPH02503919A JPH02503919A JP63506040A JP50604088A JPH02503919A JP H02503919 A JPH02503919 A JP H02503919A JP 63506040 A JP63506040 A JP 63506040A JP 50604088 A JP50604088 A JP 50604088A JP H02503919 A JPH02503919 A JP H02503919A
- Authority
- JP
- Japan
- Prior art keywords
- mbp
- rats
- disease
- administered
- autoimmune disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rehabilitation Therapy (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (19)
- 1.動物におけるT細胞媒介性またはT細胞依存性自己免疫疾患の治療法であっ て、該動物に、該自己免疫疾患に特異的な自己抗原、自己抗原の生物学的に活性 なフラグメントまたは自己抗原に構造的に類似している類似体を、該自己免疫疾 患の治療に有効な量で経口または腸内投与することからなる方法。
- 2.該自己免疫疾患が、重症筋無力症、慢性関節リウマチ、真性糖尿病、全身性 紅斑性狼瘡、多発性硬化症、自己免疫性溶血性貧血および自己免疫性甲状腺炎か らなる群から選択される請求項1に記載の方法。
- 3.該自己免疫疾患が接触感受性疾患である請求項1に記載の方法。
- 4.該接触感受性疾患が植物要素によって誘発される請求項3に記載の方法。
- 5.該植物要素が毒性アイビー由来である請求項4に記載の方法。
- 6.該動物への該経口または腸内投与が該自己免疫疾患の発症前に行われる請求 項1に記載の方法。
- 7.該動物への該経口または腸内投与が該自己免疫疾患の発症後に行われる請求 項1に記載の方法。
- 8.該治療が該動物における該自己免疫疾患の発症を防ぐ請求項6に記載の方法 。
- 9.該治療が該動物における該自己免疫疾患の症状を抑制する請求項7に記載の 方法。
- 10.該動物がヒトである請求項1〜9のいずれかに記載の方法。
- 11.該自己抗原が経口投与される請求項1に記載の方法。
- 12.該自己抗原が腸内投与される請求項1に記載の方法。
- 13.該自己免疫疾患が多発性硬化症である請求項2に記載の方法。
- 14.該自己免疫疾患が慢性関節リウマチである請求項2に記載の方法。
- 15.該自己抗原がMBP、MBPの生物学的に活性なフラグメントまたはMB Pの類似体である請求項13に記載の方法。
- 16.MBPの該生物学的に活性なフラグメントがMBPの脳炎非誘発性フラグ メントである請求項15に記載の方法。
- 17.MBPの該脳炎非誘発性フラグメントがMBPのアミノ酸1−37または その生物学的に活性な部分を含む請求項16に記載の方法。
- 18.MBPの該生物学的に活性な部分がアミノ酸5〜20の領域を含む請求項 17に記載の方法。
- 19.MBPのアミノ酸1−37、その生物学的に活性なフラグメントまたはそ の類似体を含むポリペプチド。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6573487A | 1987-06-24 | 1987-06-24 | |
US065734 | 1987-06-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02503919A true JPH02503919A (ja) | 1990-11-15 |
JP2512796B2 JP2512796B2 (ja) | 1996-07-03 |
Family
ID=22064733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63506040A Expired - Lifetime JP2512796B2 (ja) | 1987-06-24 | 1988-06-24 | 自己抗原の経口投与による自己免疫疾患の治療法 |
Country Status (8)
Country | Link |
---|---|
EP (2) | EP0359783B2 (ja) |
JP (1) | JP2512796B2 (ja) |
AT (2) | ATE130762T1 (ja) |
AU (1) | AU632991B2 (ja) |
CA (1) | CA1336954C (ja) |
DE (2) | DE3854741T3 (ja) |
DK (1) | DK175666B1 (ja) |
WO (1) | WO1988010120A1 (ja) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5869054A (en) * | 1987-06-24 | 1999-02-09 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of autoantigens |
US5571500A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases through administration by inhalation of autoantigens |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US6645504B1 (en) | 1987-06-24 | 2003-11-11 | Autoimmune Inc. | Bystander suppression of type I diabetes by oral administration of glucagon |
US5645820A (en) * | 1987-06-24 | 1997-07-08 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
US5641474A (en) * | 1987-06-24 | 1997-06-24 | Autoimmune, Inc. | Prevention of autoimmune diseases by aerosol administration of autoantigens |
US5843445A (en) * | 1987-06-24 | 1998-12-01 | Autoimmune, Inc. | Method of treating rheumatoid arthritis with type II collagen |
US5571499A (en) * | 1987-06-24 | 1996-11-05 | Autoimmune, Inc. | Treatment of autoimmune diseases by aerosol administration of autoantigens |
CA1340012C (en) * | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
ATE98872T1 (de) * | 1988-11-03 | 1994-01-15 | Schering Corp | Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie. |
NO306996B1 (no) * | 1989-02-17 | 2000-01-24 | Bayer Ag | Isolert bukspyttkjerteloey-celle-(ICA)-antigen for in vitro- bruk |
IL89431A0 (en) * | 1989-02-27 | 1989-09-10 | Yeda Res & Dev | Pharmaceutical compositions for the treatment of autoimmune diseases |
DE69031563T2 (de) * | 1989-07-14 | 1998-02-12 | Autoimmune, Inc., Lexington, Mass. | Behandlung der autoimmunen uveoretinitis in menschen |
ES2144398T3 (es) * | 1989-12-20 | 2000-06-16 | Autoimmune Inc | Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos. |
US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
DE69123256T2 (de) * | 1990-09-28 | 1997-06-12 | British Tech Group | Antigen-antikörperkonjugaten |
IL99699A (en) * | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
CA2092905C (en) * | 1990-10-15 | 2002-01-08 | Howard L. Weiner | Treatment of autoimmune diseases by oral administration of autoantigens |
GB2251186A (en) * | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
US6252040B1 (en) | 1991-10-22 | 2001-06-26 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
US5817629A (en) | 1991-10-22 | 1998-10-06 | The Governors Of The University Of Alberta | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
EP0705108A4 (en) * | 1993-06-02 | 1997-08-06 | Tvw Telethon Inst Child Health | USE OF CRYPTIC PEPTIDES FOR INDUCTION IMMUNOLOGICAL TOLERANCE |
GB9319429D0 (en) | 1993-09-21 | 1993-11-03 | London Health Ass | Methods and products for controlling immune responses in mammals |
CZ122697A3 (en) * | 1994-10-25 | 1997-09-17 | Immulogic Pharma Corp | Preparations and methods of treating disseminated sclerosis |
US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6379670B1 (en) | 1994-11-18 | 2002-04-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
US5856446A (en) * | 1995-07-07 | 1999-01-05 | Autoimmune Inc. | Method of treating rheumatoid arthritis with low dose type II collagen |
US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
KR19990071782A (ko) * | 1996-01-05 | 1999-09-27 | 왈리스 조 앤 | 유형ⅱ 콜라겐의 제조방법 |
IL131025A0 (en) * | 1997-01-24 | 2001-01-28 | Autoimmune Inc | Treatment of autoimmune disease using tolerization in combination with methotrexate |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US6913745B1 (en) | 1997-12-02 | 2005-07-05 | Neuralab Limited | Passive immunization of Alzheimer's disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US6710226B1 (en) | 1997-12-02 | 2004-03-23 | Neuralab Limited | Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
US6923964B1 (en) | 1997-12-02 | 2005-08-02 | Neuralab Limited | Active immunization of AScr for prion disorders |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
WO1999030736A2 (en) | 1997-12-16 | 1999-06-24 | Regents Of The University Of Minnesota | Methods to treat undesirable immune responses |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES BY COPOLYMER 1 AND SIMILAR COPOLYMERS AND PEPTIDES |
ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
US6812205B2 (en) | 2000-03-15 | 2004-11-02 | The Brigham & Women's Hospital, Inc. | Suppression of vascular disorders by mucosal administration of heat shock protein peptides |
US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
HU229377B1 (hu) | 2000-08-21 | 2013-11-28 | Apitope Technology Bristol Ltd | Tolerogén humán peptidek |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
WO2004112833A1 (en) | 2003-06-23 | 2004-12-29 | Biotech Tools Sa | Epitope composition for sublingual, buccal or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
EP2182983B1 (en) | 2007-07-27 | 2014-05-21 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases with humanised anti-abeta antibodies |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3989819A (en) * | 1969-03-05 | 1976-11-02 | American Cyanamid Company | Process for separating proteins from central nervous system tissue and treating experimentally induced demyelinating diseases |
US4350682A (en) † | 1979-05-11 | 1982-09-21 | Lescarden Ltd. | Cartilage extraction processes and products |
KR880701108A (ko) † | 1986-06-30 | 1988-07-25 | 원본미기재 | 면역조절 조성물 및 이들의 용도 |
CA1340012C (en) † | 1987-08-17 | 1998-08-25 | Trustees Of Leland Stanford Jr. University | Peptide determinant associated with immunity |
GB8803881D0 (en) * | 1988-02-19 | 1988-03-23 | Traqson Ltd | Novel photoactive compounds processes for their production & intermediates thereof |
AU3320089A (en) * | 1988-04-20 | 1989-10-26 | Hartech (Australia) Pty. Ltd. | Portable traffic lights |
-
1988
- 1988-06-24 JP JP63506040A patent/JP2512796B2/ja not_active Expired - Lifetime
- 1988-06-24 AT AT88906457T patent/ATE130762T1/de not_active IP Right Cessation
- 1988-06-24 WO PCT/US1988/002139 patent/WO1988010120A1/en active IP Right Grant
- 1988-06-24 AU AU20797/88A patent/AU632991B2/en not_active Expired
- 1988-06-24 EP EP88906457A patent/EP0359783B2/en not_active Expired - Lifetime
- 1988-06-24 AT AT95102528T patent/ATE258065T1/de not_active IP Right Cessation
- 1988-06-24 CA CA000570406A patent/CA1336954C/en not_active Expired - Fee Related
- 1988-06-24 DE DE3854741T patent/DE3854741T3/de not_active Expired - Lifetime
- 1988-06-24 EP EP95102528A patent/EP0666080B1/en not_active Expired - Lifetime
- 1988-06-24 DE DE3856566T patent/DE3856566T2/de not_active Expired - Lifetime
-
1989
- 1989-12-20 DK DK198906516A patent/DK175666B1/da not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE3854741D1 (de) | 1996-01-11 |
DK651689D0 (da) | 1989-12-20 |
AU2079788A (en) | 1989-01-19 |
EP0666080A1 (en) | 1995-08-09 |
WO1988010120A1 (en) | 1988-12-29 |
ATE130762T1 (de) | 1995-12-15 |
DE3854741T3 (de) | 2002-08-14 |
EP0359783B2 (en) | 2002-04-17 |
DE3856566D1 (de) | 2004-02-26 |
EP0359783A1 (en) | 1990-03-28 |
EP0359783A4 (en) | 1990-06-27 |
EP0359783B1 (en) | 1995-11-29 |
DK651689A (da) | 1990-02-26 |
DE3854741T2 (de) | 1996-04-18 |
AU632991B2 (en) | 1993-01-21 |
ATE258065T1 (de) | 2004-02-15 |
DE3856566T2 (de) | 2004-06-24 |
JP2512796B2 (ja) | 1996-07-03 |
EP0666080B1 (en) | 2004-01-21 |
CA1336954C (en) | 1995-09-12 |
DK175666B1 (da) | 2005-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH02503919A (ja) | 自己抗原の経口投与による自己免疫疾患の治療法 | |
US5869054A (en) | Treatment of multiple sclerosis by oral administration of autoantigens | |
JP2635444B2 (ja) | 自己抗体の経口投与による自己免疫性疾患の治療 | |
US20050208061A1 (en) | Treatment of autoimmune diseases by oral administration of autoantigens | |
US5849298A (en) | Treatment of multiple sclerosis by oral administration of bovine myelin | |
EP0594607B1 (en) | Enhancement of the down-regulation of autoimmune diseases by oral or enteral administration of autoantigens | |
Bergström et al. | The effect of thoracic duct lymph drainage in myasthenia gravis | |
JPH05508663A (ja) | 哺乳動物における異系移植片拒否反応を抑制するための方法と組成物 | |
US7097845B2 (en) | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance | |
US5961977A (en) | Method of treating or preventing autoimmune uveoretinitis in mammals | |
JP3875730B2 (ja) | 自己免疫疾患の予防治療剤 | |
JPH05502854A (ja) | 寛容原性イムノグロブリン―蛋白質結合体 | |
South et al. | The IgA antibody system | |
Castro | Immunology for surgeons | |
Seddon et al. | Deaggregated homologous immunoglobulin‐peptide conjugates induce peptide‐specific T cell nonresponsiveness in vivo | |
JP2001029067A (ja) | 抗原特異的細胞傷害抑制性細胞の誘導方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080430 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090430 Year of fee payment: 13 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090430 Year of fee payment: 13 |